Ovagen (20mg) is a synthetic short-peptide material supplied exclusively for controlled laboratory research. It is commonly classified within the peptide bioregulator category and may be used as a test article in analytical, in vitro, and other appropriately controlled experimental settings.
For laboratory research use only. Not for human or animal consumption.
Nordsci provides lot-specific analytical documentation for research materials. Researchers should review the applicable Certificate of Analysis for information regarding compound identity, analytical purity, and the testing methods used for the specific lot.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Ovagen (20mg) is supplied as a synthetic short-peptide research material for analytical evaluation and controlled laboratory experimentation. Published research discussions have associated this class of peptide with organ-specific and reproductive-tissue research models. These associations provide a basis for laboratory investigation and do not establish a clinical, diagnostic, or therapeutic application.
Ovagen should only be handled by qualified research personnel operating within appropriately equipped laboratory environments. No information on this page should be interpreted as dosing, administration, or application guidance.
Ovagen (20mg) – Research Specifications:
| Compound | Ovagen |
| Quantity | 20mg per vial |
| Compound Type | Synthetic short-peptide research material |
| Form | Lyophilized powder |
| Purity / Identity | Refer to the applicable lot-specific Certificate of Analysis |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, light, and moisture |
| Intended Use | Controlled laboratory research and analytical evaluation only |
| Restricted Uses | Not for human or animal consumption, in-vivo use, diagnostic use, therapeutic use, or use as a food, drug, cosmetic, or dietary supplement |
Ovagen is a synthetic short-peptide compound commonly categorized among peptide bioregulator research materials. It has appeared in research discussions involving short peptide sequences, cellular signaling models, and organ-specific experimental systems.
In laboratory settings, Ovagen may be evaluated through analytical characterization, in vitro assay development, peptide stability testing, or other controlled experimental methodologies. References to ovarian, reproductive, or endocrine research describe areas of scientific investigation and should not be interpreted as evidence of a physiological benefit or approved application.
Important Research Notice: Nordsci research materials are accompanied by lot-specific analytical documentation when available. Researchers should consult the applicable Certificate of Analysis for reported test methods, compound identity information, and analytical results.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
Ovagen may be included as a test article in controlled laboratory models examining short-peptide signaling concepts described in relation to reproductive tissues. Research design, controls, endpoints, and interpretation remain the responsibility of the investigating laboratory.
Laboratory researchers may use Ovagen in exploratory in vitro models involving molecular communication pathways discussed within endocrine research. Its inclusion in an experiment does not imply a validated effect, clinical outcome, or therapeutic application.
Ovagen may be evaluated in controlled experimental models designed to observe peptide-related variables associated with ovarian cell cultures or tissue-specific research systems. The title of this research category does not represent a claim that Ovagen maintains, restores, or alters ovarian function.
Researchers may evaluate Ovagen as a laboratory test article in assays involving cellular signaling, peptide characterization, gene-expression measurement, or related molecular research methodologies. Outcomes depend on the selected model, assay conditions, controls, and analytical methods.
Ovagen (20mg) should be handled by qualified laboratory personnel according to applicable institutional procedures for research materials. Laboratories should document storage conditions, sample preparation, experimental controls, analytical methods, and material traceability.
Protocol Design Considerations: Experimental results can be affected by material concentration, assay design, sample preparation, environmental conditions, analytical sensitivity, control selection, and laboratory handling practices. Researchers should use validated procedures appropriate to their specific experimental model.
This information is provided solely as a general laboratory reference. It does not provide dosing, administration, diagnostic, therapeutic, or in-vivo application instructions.
Lot-specific Certificates of Analysis provide the analytical information reported for individual Ovagen lots. Researchers should consult the applicable COA to review identity, purity, testing methodology, and other available analytical data.
The presence of a COA does not establish that the material is suitable for human use, veterinary use, clinical use, diagnostic use, or any other unapproved application.
Nordsci Peptides supplies Ovagen (20mg) exclusively as a laboratory research material. Laboratories evaluating research suppliers should review lot-specific analytical documentation, product labeling, storage information, material traceability, and institutional purchasing requirements before procurement.
IMPORTANT: Ovagen (20mg) is not approved for human or veterinary use. It is not a drug, food, cosmetic, medical product, or dietary supplement. Researchers and purchasing institutions are responsible for compliance with all applicable laws, regulations, institutional policies, and laboratory safety requirements.
Researchers should consult independently verified, peer-reviewed scientific literature relevant to their specific experimental model. References should be evaluated for methodology, compound identity, experimental conditions, and direct applicability to Ovagen before being cited or relied upon.
No statement on this product page should be interpreted as representing established clinical efficacy, safety, diagnostic utility, or therapeutic suitability.
